Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

About this update from Medtronic Plc.

[{"type":"text","content":"Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"GALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.","length":239,"tagName":"p"},{"type":"text","content":"Q3 Key Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidance","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-point","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Company reiterates FY26 organic revenue growth and EPS guidance","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Cardiac Ablation Solutions revenue increased 80%, including 137% in the U.S., on strength of pulsed field ablation (PFA) portfolio","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured CE Mark for Sphere-360™ and initiated U.S. pivotal trial","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured U.S. FDA clearance for Hugo™ robotic-assisted surgery; first cases completed this month","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured U.S. FDA clearance for Stealth AXiS™ Surgical System for spinal procedures","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Diabetes revenue increased 8.3% led by double-digit strength in International markets","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Executing M&A strategy with two key transactions in the quarter: CathWorks in Coronary and Renal Denervation and Anteris in Structural Heart","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":869,"olType":false},{"type":"text","content":""Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio," said Geoff Martha, Medtronic chairman and chief executive officer. "By unlocking new markets and investin...

More updates from Medtronic Plc.